Cordyceps Sunshine Biotech Holdings Co., Ltd. Annual Report Review

I have reviewed the latest filings for Cordyceps Sunshine Biotech. The company is aggressively trying to expand, but its financial health remains shaky. If you are considering an investment, look past the marketing and understand the significant risks involved.

1. What does this company do?

Cordyceps Sunshine Biotech is a Taiwan-based company selling health supplements, including oral shots, chocolate, and pet care products. They have moved away from their original "Cordyceps" business entirely. With a lean team of 16 employees, they sell through their own physical stores in Taiwan and e-commerce partners in Hong Kong and China. They rely on third-party manufacturers, which limits their direct control over supply chain quality and production costs.

2. Financial Performance: A Troubling Trend

The company’s financial health shows several areas of concern:

• Profit/Loss: The company is currently operating at a loss. While the loss narrowed from $226,258 in 2024 to $154,822 in 2025, the business has not yet achieved profitability.
• Revenue & Sales: Total revenue remained flat. A notable trend is the reliance on "related parties." Sales to Gasar Biotechnology, a company connected to management, increased by over 231% compared to the previous year.
• Margins: The gross margin dropped from 72% in 2024 to 61% in 2025. This decline indicates that the company has had to lower prices to move inventory in a competitive market.

3. Cash Flow & Survival: The "Going Concern" Warning

The company faces a working capital deficit of over $4.19 million, meaning their short-term liabilities significantly exceed their available cash. Operations are currently sustained through interest-free loans provided by company leadership. The company has formally acknowledged that there is "substantial doubt" regarding its ability to continue as a going concern due to these cash flow constraints.

4. Governance & Internal Controls

Management has identified that their internal financial controls are ineffective. The company lacks sufficient staff trained in U.S. accounting standards and does not maintain a comprehensive manual for its financial reporting, increasing the risk of accounting errors. Additionally, the company has changed its accounting firm three times in less than two years.

5. Tax & Legal Risks

• PFIC Risk: U.S. investors should be aware that the company may be classified as a "Passive Foreign Investment Company" (PFIC), which can result in unfavorable tax treatment for shareholders.
• Limited Oversight: As a Cayman Islands-incorporated entity, shareholders have restricted rights to inspect company books. Furthermore, the company does not carry product liability insurance, leaving it exposed to significant financial risk in the event of legal claims.

6. The Bottom Line

Cordyceps Sunshine Biotech is currently operating under significant financial pressure. The combination of reliance on internal sales, frequent auditor turnover, and ineffective internal controls suggests a high level of risk. Investors should carefully weigh these factors against the company's current inability to sustain its business model through independent market success.